Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|23|10|1533-1539

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.10, 2017-05, pp. : 1533-1539

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dyslipidemia in the metabolic syndrome

By Chan Dick   Watts Gerald  

The Journal of Drug Evaluation, Vol. 2, Iss. 1, 2004-01 ,pp. : 3-34

Taylor & Francis Ltd

Access to resources Recommend Favorite

Editorial: The Different Facets of Diabetes, Dyslipidemia and Hypertension in Cardio-metabolic Diseases: Current Perspective and Future Developments

By  

Current Pharmaceutical Design, Vol. 23, Iss. 10, 2017-05 ,pp. : 1425-1426

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacotherapy of Mixed Dyslipidemia in the Metabolic Syndrome

By  

Current Clinical Pharmacology, Vol. 5, Iss. 2, 2010-05 ,pp. : 133-139

Bentham Science Publishers

Access to resources Recommend Favorite

Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus

By Reyes-Soffer Gissette   Rondon-Clavo Carlos   Ginsberg Henry N  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1429-1438

Informa Healthcare

Access to resources Recommend Favorite

Drug Combinations for Dyslipidemia and Obesity Treatment in Metabolic Syndrome

By  

Current Pharmaceutical Design, Vol. 15, Iss. 29, 2009-10 ,pp. : 3446-3462

Bentham Science Publishers

Access to resources Recommend Favorite